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Glycan1. Introduction
Antibodies, also known as immunoglobulins (Ig), are naturally
produced by plasma cells derived from B cells and play a key role in
humoral immunity. Human antibodies are classiﬁed into ﬁve
isotypes (IgA, IgD, IgE, IgG and IgM) each with distinct structure
and biological activity and the heavy chain within each class are des-
ignated α, δ, ε, γ and μ, respectively [1]. Among these ﬁve antibody
isotypes, IgG has the longest serum half-life, is the most abundant
(~75%) in circulation [2] and is the only isotype used in licensed re-
combinant monoclonal antibody therapeutics. These recombinant
therapies have mainly utilized the IgG1 subclass [3] and have been
developed to treat a large range of diseases such as cancer, autoim-
munity and inﬂammation.
One promising strategy to improve the efﬁcacy of therapeutic an-
tibodies is manipulation of antibody glycosylation [4]. Normal serum
human IgG contains multiple glycoforms due to the addition of di-
verse complex biantennary oligosaccharides in the IgG Fc domain.
Although the IgG Fc glycans do not affect antigen binding by the an-
tibody Fab domains, they are essential to the IgG effector functions.
For example, antibody-dependent cellular cytotoxicity (ADCC) can
be greatly enhanced by removal of the core fucose residue from then personalisedmedicine" Gues
n).
. This is an open access articletunderIgG Fc glycan [5–8] (Fig. 1). Conversely, the addition of terminal sialic
acid residues to the IgG Fc glycan has been reported to suppress
autoantibody-driven inﬂammation [9–12]. In this review, we discuss
the structure and activity of different IgG antibody glycoforms and
highlight the emerging strategies of antibody glycoengineering to
augment biotherapeutic attributes. Overall, we outline the current
knowledge of structure-based IgG glycoform engineering.2. Overview of Fc structure and effector functions
The monomeric form of IgG represents the prototypical antibody
structure. It has an overall Y-shaped structure with two ~50 kDa
heavy chains and two ~25 kDa light chains, each of which contains a
variable (V) and a constant (C) region [13,14]. The heavy (γ) chains of
IgG consist of four Ig domains, VH, Cγ1, Cγ2 and Cγ3, the light (either
κ- or λ-type) chains consist of two Ig domains, VL and CL. Together,
the heavy and light chains form three distinctive features of an anti-
body: the antigen-binding domain F(ab′)2, the ﬂexible hinge region,
and the Fc domain (Fig. 1A). The Fc domain promotes effector functions
via interactions with the complement system and the cellular Fcγ re-
ceptors (FcγRs) present on various immune cells [15].
Human IgGs can be further divided into four subclasses, IgG1, IgG2,
IgG3 and IgG4, which are named in order of decreasing abundance
[16]. Different subclasses can extend different effector functions. For ex-
ample, IgG1 and IgG3 trigger the classical route of complementmore ef-
ﬁciently than IgG2 and IgG4 [17–19]. Another major distinction is thatthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Overall architecture of IgG, the IgG Fc domain, and the interaction with FcγRIIIa.
(A) Crystal structure of an intact human IgG1 with the protein moiety shown in gray
and the glycans as sticks. Monosaccharide residues are coloured: mannose (green),
fucose (red). galactose (yellow), N-acetylglucosamine (blue). PDB ID: 1HZH [281,282].
(B) Crystal structure of an isolated fucosylated IgG1 Fc domain (PDB ID: 3AVE) [47]. (C
and D) Fucosylation of IgG Fc glycan impairs FcγRIIIA binding through a steric clash
with the Asn162 glycan of the receptor (transparent surface; green, no clash; red, clash
with Fc fucose).
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[20]. Between IgG1 and IgG3, the afﬁnity of IgG3 tomost FcγRs tends to
exceed that of IgG1 [20]. The four human IgG subclasses sequences are
relatively conserved. However, the length and ﬂexibility of their hinge
regions vary extensively with IgG3 [62 amino acids (aa)] N IgG1 (15
aa) N IgG2 = IgG4 (12 aa); yet, in terms of the hinge ﬂexibility, the
order is: IgG3 N IgG1 N IgG4 N IgG2 [21,22]. This variation in ﬂexibility
is likely impacted by the variable number of interchain disulphides
across the antibody classes.
The IgG1 Fc domain mediates antibody effector functions and is
structured as a horseshoe-like homodimer comprising of the Cγ2
and Cγ3 domains that are linked together by two interchain di-
sulphide bonds at the lower hinge [23]. The Fc domain contains var-
ious binding sites for several host and bacterial proteins as well as
the human cytosolic Fc binding protein, TRIM21, that relocates IgG
bound virion complexes to the proteasome for degradation [24].
While the FcγRs and complement molecule C1q interact with the
Cγ2 domain and the lower hinge region, bacterial staphylococcal
protein A and the neonatal Fc receptor (FcRn) bind to the interface
of Cγ2 and Cγ3 domains [25–27]. The two opposing Cγ3 domains
form extensive hydrophobic interactions that involve more than 20
residues per chain. In contrast, the interaction between the opposing
and ﬂexible Cγ2 domains is principally through the conserved N-
linked glycan attached at Asn297, which projects along the surface
of the Cγ2 domains and occupies the interstitial space between do-
mains [23]. The changes in naturally occurring and engineered Fc
glycosylation and how they affect IgG structure and effector func-
tions will be discussed in more detail in subsequent sections.3. Antibody glycoforms
3.1. Biogenesis and typical serum composition of human antibody
glycoforms
Antibody N-linked glycans are assembled via the conserved endo-
plasmic reticulum (ER) and Golgi glycosylation pathway. Interestingly,
Fc glycosylation largely remains consistent when isolated from human
serum as well as from different recombinant expression systems. The
glycans are not homogeneous but do not exhibit the very signiﬁcant
heterogeneity, often characteristic of other glycoproteinswithmore sol-
vent accessible glycans, due to extensive intramolecular glycan-protein
interaction within the Fc.
Like all glycoproteins, IgG N-linked glycans are added co-
translationally in the ER to the amide nitrogen of the asparagine (Asn)
side chain within the glycosylation sequon (Asn-X-Ser/Thr, where X is
any amino acid except Pro). Glycosylation is initiated by the en bloc
transfer of Glc3Man9GlcNAc2 from a Glc3Man9GlcNAc2-pyrophos-
phate-dolichol precursor by oligosaccharyltransferase to a nascent poly-
peptide in the lumen of the ER. The glucosylated N-glycan structure is
then modiﬁed by a series of glycosidases and glycosyltransferases dur-
ing transit through the secretory system. After protein folding and initial
trimming by the ER-resident glucosidases I and II and α-mannosidase,
the nascent antibody is released from the calnexin–calreticulin quality
control checkpoint and enters the Golgi apparatus where further glycan
processing occurs. Glycan processing in the Golgi combines both glycan
trimming, catalysed by mannosidases I and II, as well as stepwise addi-
tion of individual monosaccharide residues, catalysed by GlcNAc-
transferases I, II and III (GnT I, II and III), fucosyltransferases (FucT),
galactosyltransferases (GalT) and sialyltransferases (SiaT), leading to a
diversity of IgG glycoforms [28]. While the IgG glycans display a charac-
teristic signature of partial galactosylation, aswell as other features, this
signature does vary between individuals and disease states [29].
Mass spectrometric and X-ray crystallographic analyses indicate
that glycan pairings at the two Asn297 sites on IgG-Fc can be asym-
metric, which further increases the diversity of IgG glycoforms [30,
31]. Overall, IgG N-glycans are predominantly biantennary struc-
tures with differences in the degree of fucosylation, sialylated and
galactosylation. The majority (~90%) of human IgG-Fc glycans are
core-fucosylated, out of which a-, mono- and bigalactosylated
forms account for ~30%, ~35% and ~16% of the total glycan pool, re-
spectively [32,33]. About 15% of human IgG-Fc glycans contain a
GnT III-mediated bisecting GlcNAc [33,34]. In serum, a trace amount
of bisecting GlcNAc residues are also modiﬁed by galactosylation
[35]. Only a small proportion of serum IgG Fc glycans are sialylated,
with monosialylated and disialylated glycoforms accounting for ap-
proximately 5–10% and 1%, respectively [1,33,37,38].
In addition to the conserved glycosylation Asn297 site on IgG Fc,
roughly 15–20% of polyclonal human IgGs are glycosylated in the vari-
able regions of the heavy chain, light chain, or both, of the Fab regions
[38–40]. The Fab N-glycans contain more sialic acid, galactose and
bisecting GlcNAc residues than Fc glycans [38,39,41]. It should be
noted that, unlike the N-glycans on IgG Fc, those on IgG-Fab are refrac-
tory to release by peptide-N-glycosidase F (PNGase F) [34,42]. Although
the functional signiﬁcance of IgG Fab glycosylation has not been fully
evaluated, results frommonoclonal antibodies (mAbs) suggest that gly-
cosylation in the variable regions of the kappa (Vκ), the lambda (Vλ)
light chains or the heavy chains (VH) can have a neutral, positive or neg-
ative inﬂuence on antigen binding [34].
3.2. Cellular production of antibody Fc glycoforms
Analysis of Fc glycoforms by X-ray crystallography and nuclearmag-
netic resonance (NMR) spectroscopy have shaped our understanding of
the factors inﬂuencing natural antibody glycosylation and have provid-
ed a structural rationale for biophysical and functional effects of glycan
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glycoengineering strategies in the preparation of the target antibody
glycoform. These strategies are outlined in Section 4, below.
Interestingly, the available crystallographic data almost completely
characterizes the structure of the Fc domain throughout the natural bio-
synthetic stages of glycan remodelling (Fig. 2). Analysis of this panel of
structures provides a detailed understanding of the decisive stage in
complex-glycan biosynthesis and the generation of a class of thermody-
namically more stable complex-type glycoforms [44–49].
Regardless of the glycoform, the interaction between the protein
surface and both the Manβ1–4GlcNAcβ1–4GlcNAc core and what
can be observed of the 3-arm, is conserved [44]. In contrast, the 6-
arm residues exhibit divergent conformations reﬂecting the differ-
ential chemical compositions and/or surrounding environments of
glycan residues. One of the major changes in protein-glycan packing
during Fc glycan biogenesis occurs during the transition from hybrid
type to complex type. During this transition, Golgi α-mannosidase II
processing ﬁrst causes the relaxation of the 6-arm toward the pro-
tein surface. Next, GnT II catalyses the transfer of β1,2-linked GlcNAc
to the 6-arm core mannose (Man4ʹ) to form the hydrophobic stack-
ing interactions between GlcNAc5ʹ and Phe243 (Fig. 2). Such
glycan-protein stacking interactions have been shown to increase
Fc stability while suppressing subsequent enzymatic processing of
Fc glycan [44]. This can be further rationalized by considering the im-
pact of such stabilizing interactions on the dynamics of the system.
NMR studies utilizing 13C labelled terminal galactose residues have
shown that approximately half of the glycan population at physio-
logical temperature is highly ﬂexible with the remaining conforma-
tion exhibiting relaxation rates concomitant with the protein-
bound conﬁguration [50]. In this way, stabilizing interactions drive
the population into a conformation that is less accessible to
sialyltransferases [51].
The structure of the sialylated Fc has been extensively debated
mainly in the context of understanding the mechanism of the puta-
tive anti-inﬂammatory activity of α2,6-sialylated immunoglobu-
lins. Sondermann et al. hypothesized that α2,6-linked sialylation
on the 6-arm would bind to the protein surface driving substantial
conformation changes [52,53]. However, NMR analysis by Barb
et al. concludes that “sialylation of either branch terminus does
not appear to dramatically alter the motional behavior of the N-Fig. 2. Crystal structures of the glycosylated Cγ2 domain of IgG Fc glycoforms. The following s
GlcNAc; green circles, Man; red diamonds with black dot, fucose; stars, sialic acid. Linkage pos
forward slash, 3-link; horizontal line, 4-link; back slash, 6-link). Anomericity is indicated by u
[284] is used for labeling residues within oligomannose- and biantennary-type oligosaccharid
fucose [285]. PDB IDs are displayed in the ﬁgure [44–49]. Residues not evident in the electronglycan as judged by solution NMR spectroscopy” [54]. Furthermore,
two independent crystallographic analyses revealed that the 6-arm
sialic acid was projecting away from the protein-bound galactose
residue in an entirely solvent accessible manner [45,55] (Fig. 3A).
In contrast, those structures suggest that α2,3-sialylation that
could occur in recombinant antibody glycosylation would prevent
the formation of the canonical galactose-protein interactions with
the potential for longer range destabilizing effects through the 6-
arm. Evidence for this comes from recent hydrogen-deuterium
exchange mass spectrometry (HDXMS) studies which while not ex-
amining the naturally occurring α2,6-sialylated glycoforms, pre-
sented evidence of destabilisation upon α2,3-sialylation [56]. In
addition, the HDXMS analysis conﬁrmed elevated regional solvent
accessibility of protein predicted by the crystal structures of the
oligomannose and hybrid-type Fc glycoforms [44].
4. Emerging strategies for antibody glycoengineering
An important feature of antibody glycosylation is not only the struc-
tural heterogeneity and complexity of glycans but also the observation
that minor structural changes signiﬁcantly affect the effector functions
of antibodies. Thus, the preparation of homogeneous antibody
glycoforms is important both for fundamental structure–function rela-
tionship studies and for therapeutic applications. Strategies that allow
a greater control of antibody glycosylation proﬁles mainly involve ma-
nipulations of host biosynthetic pathways and/or in vitro chemo-
enzymatic glycosylation remodelling [57,58].
4.1. Manipulations of host biosynthetic pathways
4.1.1. Glycoengineering in mammalian cells
Mammalian cells, especially Chinese hamster ovary (CHO) cells, are
the predominant system for the production of therapeutic monoclonal
antibodies (mAbs). Since afucosylated antibodies have been reported
to exhibit enhanced ADCC, a property that is favourable for cancer ther-
apy [59–61], considerable efforts have been focused on creatingmutant
cell lines capable of producing non-fucosylated antibodies. One way to
achieve this is to knockdown or knockout the FUT8 gene, which encodes
the α1,6-fucosyltransferase (α1,6-FucT) that catalyses the transfer of
fucose from GDP-fucose to the innermost GlcNAc residue of the tri-ymbols were used to represent glycans [283]: yellow diamonds, galactose; blue squares,
itions are shown by the angle of the lines linking the sugar residues (vertical line, 2-link;
nbroken lines for β-bonds and broken lines for α-bonds. The system of Vliegenhart et al.
es with the additional modiﬁcations of 7 and 7′ for sialic acid, 1′ for α1→ 6-linked core
density are labelled with an asterisks.
Fig. 3. The architecture of α2,6-sialylated IgG Fc and binding to FcγRIIIa is not modulated by Fc α2,6-sialylation. (A) Crystal structure of hypersialylated human IgG1 Fc with 2Fo− Fc
electron density shown around the N-linked glycans (PDB ID: 4BYH). Panel adapted from Crispin et al. [45]. Glycan residues are coloured according to Fig. 1 (sialic acid, pink). (B) The
binding of FcγRIIIa (Val158 variant) to IgG is independent of α2,6-sialylation of IgG Fc as shown by surface plasmon resonance analysis. Panel adapted from Yu et al. [51].
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Japanese company Kyowa Hakko Kirin to create mogamulizumab
(Poteligeo®) to treat refractory adult T-cell leukemia [65]. Another ap-
proach is to knockout the mammalian GMD gene, which encodes the
enzyme GDP-mannose 4,6-dehydratase that takes part in the biosyn-
thesis of the fucose donor substrate, GDP-fucose, from GDP-mannose
[5,66,67]. Since both FUT8 and GMD genes share no redundancy and
are independently responsible for α1,6-fucosylation, double knock-
down of FUT8 and GMD also effectively allows stable expression of
fully non-fucosylated antibodies with enhanced ADCC [68].
Besides the knockout/knockdown mutagenesis, overexpression
of certain glycoprocessing enzymes in mammalian host cells can en-
rich certain glycoforms. For example, overexpression of β1,4-GlcNAc
transferase III (GnT III) in CHO cells generates antibodies enriched
with a bisecting GlcNAc residue; this addition was subsequently ob-
served to inhibit the fucosylation reaction and thus also results in an-
tibodies with reduced fucose content [69–72]. This method was the
basis of Roche's GlycArt technology, which was employed to create
obinutuzumab (Gazyva®) for the treatment of chronic lymphocytic
leukemia [73]. Furthermore, since the presence of terminal α2,6-
linked sialic acid residues in IgG Fc has been implicated for anti-
inﬂammatory activity [9–12], overexpression of α2,6-
sialyltransferases (α2,6-SiaT) in themammalian host cell to enhance
terminal sialylation has been pursued by some groups [74,75].
Recently, a method called GlycoDelete has been developed by
Meuris et al. to simplify N-glycosylation of recombinant proteins [76].
The group started with an existing GnT I-deﬁcient human embryonic
kidney (HEK) cell line, HEK293S, to ﬁrst ‘trap’ the glycoprotein glycans
as Man5GlcNAc2 [77]. Golgi-targeted expression of an endo-β-N-
acetylglucosaminidase (ENGase), endoT, in HEK293S cells allows the
Man5GlcNAc2 to be converted tomono-GlcNAc glycoproteins. Subse-
quent processing by Golgi-resident GalT and SiaT leaves glycopro-
teins with the galactosylated disaccharides (Gal-GlcNAc) or the
sialylated trisaccharides (Neu5Ac-Gal-GlcNAc). In contrast to the
many glycan structures produced by wild-type mammalian cells,GlycoDelete cells only produce three variants (mono-GlcNAc, Gal-
GlcNAc and Neu5Ac-Gal-GlcNAc) each for the two tested therapeutic
glycoproteins, the granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and an anti-CD20 mAb. Interestingly, both the normal-
ly glycosylated anti-CD20 mAb and the GlycoDelete version share
similar stability and antigenicity proﬁles. However, the GlycoDelete
antibody has two altered features. First, it has less initial clearance
from serum in mice, which might allow a reduced dosage frequency.
Second, it has lower binding afﬁnity to human Fcγ receptors. For
neutralizing therapeutic antibodies, this feature may improve safety
by reducing the risk of cytokine production and immune cell activa-
tion. However, for other therapeutic applications that require intact
effector functions of antibodies, this feature can be a limitation. Nev-
ertheless, the GlycoDelete technology sets a precedent for the sim-
pliﬁcation of otherwise heterogeneous complex glycoproteins.
In addition to the knockout/knockdown mutagenesis and
overexpression of certain glycoprocessing enzymes, the use of
glycoprocessing inhibitors can simplify or redirect glycosylation
[78]. For example, deoxynojirimycin and castanospermine inhibit
the ER glucosidases I and II to produce the Glc3Man9GlcNAc2
glycoform; deoxymannojirimycin and kifunensine inhibit the ER
α-mannosidase to produce the Man9GlcNAc2 glycoform (Fig. 2A);
and swainsonine inhibits the Golgi α-mannosidase II to produce
hybrid-based structures such as GlcNAcMan5GlcNAc2Fuc (Fig. 2B)
glycoforms.4.2. Glycoengineering in non-mammalian cells
Non-mammalian cell lines, such as those from yeasts and plants,
have been used to generate therapeutic antibodies. Although yeast,
plant and mammalian cells exhibit conserved early steps of N-
glycosylation, their processing pathways branch off at later points.
Yeast glycosylation diverges from humans after Man8GlcNAc2 is pro-
duced in the Golgi apparatus, with the hypermannosylation of the
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decorated with bisecting β1,2-xylose and core α1,3-fucose [80].
Strategies to humanize glycoproteins produced in yeast and plant
cells mainly focus on: (1) the elimination of the yeast-speciﬁc
hypermannosylated glycoforms (e.g. by knockout of the och or alg3
genes) or the plant-speciﬁc β1,2-xylose and core α1,3-fucose (e.g.
by knockout of the β1,2-xylosyltransferase (β1,2-XylT) and α1,3-
fucosyltransferase (α1,3-FucT) genes, respectively), and (2) the sub-
sequent transfer of the mammalian glycan processing enzymes (e.g.
mannosidases I and II, GnT I and II, β1,4-GalT and α2,6-SiaT) [81–93].
Examples of successful glycoengineered systems for therapeutic anti-
bodies include the production of the anti-cancer rituximab (Rituxan®)
in Pichia pastoris [88], the anti-CD30 mAb in Lemna minor [90], and the
HIV-neutralizingmAb 2G12 and the anti-tumour heteromultimeric IgM
PAT-SM6 in Nicotiana benthamiana [91,94].
4.3. In vitro chemo-enzymatic glycosylation remodelling
Besides manipulation of host biosynthetic pathways, in vitro
chemo-enzymatic glycoengineering is another attractive method to
prepare homogeneous glycoforms of mAbs [31,57,58,95]. This
chemoenzymatic synthesis comprises three main parts. First, the an-
tibody is deglycosylated by an ENGase, such as the wild type
endoglycosidase S (EndoS) from Streptococcus pyogenes. This step
ensures that the heterogeneous N-linked glycans on the Fc domain
are removed, and thus only the innermost GlcNAc or the core-
fucosylated GlcNAc is left attached to the Asn residue. Second, selec-
tive oxazoline derivatives of complex N-linked glycan structures are
prepared by chemical methods using isolated or synthetic oligosac-
charides [96–99]. The third step is transglycosylation, in which the
preformed glycan oxazoline donor allows a speciﬁc N-glycan to be
added to the GlcNAc (or fucosylated GlcNAc) acceptor to achieve a
deﬁned, homogeneous antibody glycoform. This transglycosylation
is usually catalysed by an ENGasemutant with inactivated hydrolytic
activity (e.g. EndoS D233Q, EndoA N171A, EndoA E173Q, EndoM
N175A, EndoM N175Q [100–103]). The chemo-enzymatic approach
has been successfully applied to the glycoengineering of human
IgG-Fc fragments, as well as various therapeutic mAbs such as ritux-
imab, trastuzumab (Herceptin®) and the antiviral antibody FI6 [100,
104–107].
5. Therapeutic exploitation of antibody glycoforms
5.1. Enhancing cell killing activity by defucosylation
Removal of the α1,6-linked core fucose from IgG-Fc glycans has
been shown to signiﬁcantly increase the Fc binding afﬁnity for the
activatory FcγRIIIa receptor with enhanced natural killer (NK)
cell-mediated ADCC [5–8,64,108–111] (Fig. 1C). Since ADCC is one
of the major mechanisms responsible for the clinical efﬁcacy of
mAb in cancer therapies [112–115], defucosylated antibodies are
perceived to be more potent than their fucosylated counterparts.
Indeed, this phenomenon has been repeatedly observed in various
antigen/antibody combinations, including defucosylated anti-
CD19, anti-CD20, anti-Her2, anti-IL-5R and anti-CCR4 antibodies
[5,6,116–120]. Although the increase of bisecting GlcNAc residues
by overexpression of GnT III from CHO cells was reported to in-
crease ADCC activity [69,72], this phenomenon was later rational-
ized by the GnT III-mediated inhibition the α1,6-linked core
fucosylation [6]. Thus, it seems that the absence of fucose, but not
the presence of this bisecting GlcNAc per se, plays a critical role in
ADCC enhancement.
When a non-complexed fucosylated IgG1 Fc fragment was com-
pared with a non-complexed defucosylated counterpart, they were
shown to have almost identical structures [121]. However, a crystal
structure of the defucosylated Fc-FcγRIIIa complex revealed thatthe N-glycan attached to the Asn162 of FcγRIIIa interacts directly with
the core pentasaccharide of Fc glycan [71,122,123] (Fig. 1C). Moreover,
NMR data indicated that defucosylation increases the incidence of the
active conformation of the Tyr296 of Fc and thus accelerates the forma-
tion of a high-afﬁnity complex [123]. Also, thermodynamic data showed
that defucosylation enhances binding enthalpy and association rate
between IgG1 and FcγRIIIa [7]. In contrast, by steric hindrance, the
presence of fucose inhibits positive interactions at the Fc/FcγR inter-
face, while limiting the ﬂexibility of Tyr296 to adapt to an active con-
formation favourable for the formation of a high-afﬁnity complex
[71,122,123].
In terms of the molecular and cellular mechanisms, an enhanced af-
ﬁnity between the Fc and FcγRIIIa allows a more efﬁcient activation of
FcγRIIIa-bearing NK cells. Both mononuclear leukocytes (NK cells,
monocytes,macrophages andγδ T cells) and polymorphonuclear leuko-
cytes (neutrophils, basophils and eosinophils) can mediate ADCC [124,
125]. During the ADCC reaction elicited by defucosylated antibodies, a
large number of NK cells, for example, express the activation marker
CD69 [110]. The various mechanisms employed to kill target cells
have been suggested to include the perforin/granzyme cell death path-
way [126], the FAS-ligand pathway [127], the oxidative burst pathway
[128], and/or trogocytosis [129,130].
Furthermore, endogenous serum IgG is known to inhibit therapeutic
antibody-induced ADCC [131,132]. Defucosylated antibodies, due to
their higher-afﬁnity to FcγRIIIa, can thus overcome competition from
serum IgG for binding to FcγRIIIa on NK cells. Indeed, the inhibitory ef-
fect of serum IgG onADCCwas shown to be alleviated by defucosylation
of anti-CD20 [8,133] and anti-Lewis Y [134] antibodies. However, the
capacity to circumvent the inhibitory effect of serum IgG is dependent
on target density and the serum concentration of the therapeutic anti-
body that can be achieved [135,136]. Another potential advantage of
defucosylated antibodies is their improved therapeutic activity for all
patients independent of the FcγRIIIa polymorphisms. The FcγRIIIa-Val/
Phe158 gene polymorphisms, for example, can independently predict
response to rituximab in patient with non-Hodgkin lymphoma [112,
113]. Defucosylated rituximab has been shown to reduce the difference
between ADCC activities mediated by effector cells expressing low-
afﬁnity FcγRIIIa-Phe158 and those by effector cells expressing high-
afﬁnity FcγRIIIa-Val158 [137].
Since FcγRIIIa and FcγRIIIb share very high (99%) amino acid se-
quence homology, the proposed interactions between the FcγRIIIa-
attached oligosaccharides and the IgG Fc portion can be extended
to the case of Fc-FcγRIIIb interactions. Being selectively expressed
in neutrophils but not in NK cells, the FcγRIIIb may have some
roles in antibody-dependent cellular phagocytosis (ADCP) [138]. In
a study by Shibata-Koyama et al., although defucosylated rituximab
did not induce cytotoxicicity when neutrophils were used as effector
cells, the antibody did enhance the phagocytosis of dead lymphoma
[139].
As a word of caution, it should be noted that besides FcγRIII, other
types of Fc receptors like FcγRI and FcγRII are also involved in medi-
ating IgG-dependent ADCC [140–142]. Thus, depending on the re-
cruited effector cell types, defucosylation may not universally
increase ADCC activity. This observation has been reported by
Peipp et al., who studied ADCC activities mediated by peripheral
blood mononuclear cells (PBMCs) and by polymorphonuclear neu-
trophils (PMNs) [143]. Although the defucosylated antibody did fa-
vour PBMC-mediated ADCC via activation of FcγRIII, its fucosylated
counterpart favoured PMN-mediated ADCC via FcγRIIA engagement.
5.2. Therapeutic potential of in vivo antibody deglycosylation
Autoimmune disorders refer to the condition in which the immune
system has lost its ability to self-tolerate, resulting in the destruction
of self-tissue. Accumulating evidence suggests that autoantibodies
can contribute to the disease development [144,145]. For example,
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trix are directly pathogenic even in the absence of inﬂammatory medi-
ators [146,147]. Similarly, in pemphigus patients, IgG autoantibodies
can directly bind to epidermal cells to disrupt structures that maintain
the cell–cell or cell–matrix adhesion in the skin [148,149]. Alternatively,
antibodies as constituents of immune complexes can trigger and main-
tain chronic inﬂammation, for instance, via activation of the comple-
ment cascade and/or via extensive cross-linking of FcγR-bearing cells.
Furthermore, antibodies have been shown to contribute substantially
to allograft rejection [150]. Therefore, elimination of such pathogenic
antibodies and immune complexes can be beneﬁcial for the patients.
Since deglycosylation impairs the binding of the FcγRs to the an-
tigen–antibody complex and complement activation, this strategy
has been increasingly recognized as a targeted treatment of certain
autoimmune conditions [151]. For example, immunotherapy that
targets the amyloid-β (Aβ) protein has been investigated for
Alzheimer's disease [152–156]. Despite being effective, systemic ad-
ministration of anti-Aβ antibodies using unmodiﬁed IgG can provoke
neuroinﬂammation via microglial activation and thus increases the
risk of vascular amyloid and brain microhemorrhage [156–158]. In
contrast, deglycosylated anti-Aβ antibodies greatly reduce such inci-
dents while still retaining the properties of cognition-enhancing and
amyloid sequestration [159–162]. In another study, deglycosylation
has been shown to convert pathogenic neuromyelitis optica
(NMO)-IgG autoantibodies into therapeutic blocking antibodies
[163]. Similar observations have been made in a murine model of
fetal alloimmune thrombocytopenia, in which the administration of
deglycosylated maternal alloantibodies prevents the endogenous
glycosylated autoantibodies from destroying fetal platelets [164].
The therapeutic potential of EndoS to deactivate autoantibodies
and alleviate autoimmunity has emerged over the past few years
[165–169]. Similar to many other ENGases, EndoS cleaves the β1-4
linkage between the two GlcNAc residues found in the core of the
N-linked glycan of IgG. However, EndoS is highly unusual in its lack
of cross-reactivity to other glycoproteins and in its speciﬁcity for
the complex-type biantennary glycans on serum IgG [95,170,171].
As a strategy to evade the host immune system, the bacteria release
EndoS, which deglycosylates human IgGmolecules and results in im-
paired FcγR binding and decreased complement activation through
the classical pathway [172]. Although such actions increase bacterial
survival in human blood [173], EndoS does not seem to be a major
virulence factor, at least not during systemic infections [174]. Re-
peated intravenous administration of EndoS in rabbits has been
shown to completely hydrolyse the glycans of the whole IgG pool de-
spite the generation of anti-EndoS antibodies, while causing no ad-
verse effects on the animals [175].
The molecular basis of EndoS deactivation of IgG is of considerable
interest. The X-ray crystal structure of EndoS and amodel of its encoun-
ter complex formed with the IgG1-Fc domain [176], together with the
functional analysis of fragments of EndoS and IgG [177], have shed
some light on the mechanism. EndoS has been shown to adopt a V-
shaped conformation with the glycosidase, leucine-rich repeat (LRR),
hybrid Ig, carbohydrate-binding module (CBM) and C-terminal three-
helix bundle domains [176]. Molecular modelling of the EndoS/IgG Fc
complex suggests that the glycosidase and IgG domains are crucial for
the high substrate speciﬁcity of EndoS, while the LRR domain is impor-
tant for the enzyme stability [176]. This model also predicts that glyco-
sylated antibodies enter the V shape and are trapped by the CBMduring
processing [176]. Several CBMdomain residues, namely Trp803, Arg908
and Glu833, have been identiﬁed as hot spots for binding by computa-
tional alanine scanning mutagenesis [176]. In addition, functional anal-
ysis of truncations of EndoS revealed that, although the C-terminus of
EndoS is dispensible for activity, its deletion impedes the hydrolysis of
IgG glycans [177]. Interestingly, besides full-length IgG molecules,
EndoS is also active against different IgG fragments including IgG Fc
and the IgG Cγ2 domain (with or without the hinge region) [177]. Inthe context of S. pyogenes infection, such activity may further enhance
the bacterial immune evasion strategy: EndoS continues to act on IgG
fragments produced by other S. pyogenes proteases such as SpeB and
IdeS [178].
Besides being actively explored as a potential therapy for IgG-
mediated immune diseases, EndoS can also be utilized to enhance
monoclonal antibody (mAb)-receptor interactions [171]. This ap-
plication exploits the fact that EndoS deactivates IgG molecules
with complex-type biantennary glycans rather than those with
oligomannose-type glycans. This is in contrast to the related EndoS2,
which shows activity to both complex- and oligomannose-type glycans
[179]. Thus, upon treatment with EndoS, therapeutic mAbs containing
oligomannose-type glycans could overcome FcγR saturation by
serum IgG to maintain the FcγR binding activity. Since
oligomannose Fc glycoforms fortunately exhibit high-afﬁnity bind-
ing to all human FcγRs [180–182] and since their serum clearance is
similar to that of the complex-type glycoforms [183,184], this ‘re-
ceptor refocusing’ strategy can signiﬁcantly boost the immunological
signal provided by therapeuticmAbs. This approach can also be extend-
ed to any EndoS-resistant antibodies, including aglycosylated mAbs
engineered to exhibit functional FcγR interactions [185].
Taken together, in vivo deglycosylation of antibodies represents a
promising platform for the treatment of autoimmune diseases and
EndoS-mediated cleavage of IgG opens up avenues for treating inﬂam-
mation and for enhancing mAb-receptor interactions.
5.3. Anti-inﬂammatory glycoforms and their receptors
Intravenous immunoglobulin (IVIg) preparations are derived from
the pooled plasma of thousands of healthy donors. Although IgG is the
dominant component, varying amounts of other immunoglobulin
isotypes, such as IgA or IgM, may exist in different IVIg preparations
[186]. Low-dose IVIg preparations are pro-inﬂammatory and aremainly
used in primary and secondary immunodeﬁciency disorders. In con-
trast, high-dose (~1–3 g/kg of body weight) IVIg preparations are
anti-inﬂammatory and have been licensed to treat various autoimmune
diseases, such as immunothrombocytopenia (ITP) and Guillain-Barré
syndrome, and systemic inﬂammatory conditions, such as chronic in-
ﬂammatory demyelinating polyneuropathy (CIDP) [187].
Exactly how this anti-inﬂammatory effect is mediated by IVIg has
been an active ﬁeld of research. Several mechanisms, for which the
variable F(abʹ)2 and/or the constant Fc regions are accountable,
have been proposed and covered by other reviews in depth
[188–192]. In brief, explanations for the F(abʹ)2-dependent mecha-
nisms mainly include the blocking of cellular receptors involved in
autoimmune pathology, the neutralization of autoantibodies and
the inhibition of pro-inﬂammatory mediators such as C3a or C5a
[193–197]. While such models are attractive, the isolated IVIg Fc-
fragment has been shown to be sufﬁcient for anti-inﬂammation [9,
198–202]. A role for the Fc is further supported by a requirement
for the interactions with certain Fc-binding receptors (FcγRs). They
include the activating (especially FcγRIII) and inhibitory (FcγRIIb)
members of the classical Fcγ receptors (FcγRs) [203–210], as well
as the neonatal Fc receptor (FcRn) [211,212]. Other non-traditional
inhibitory FcγRs which have been recently implicated are: (a) the si-
alic acid-binding immunoglobulin-type lectin (SIGLEC) CD22 [213],
(b) the C-type lectin receptor dendritic cell-speciﬁc intercellular ad-
hesion molecule-3-grabbing non-integrin (DC-SIGN) [199,214,215],
(c) the C-type lectin dendritic cell immunoreceptor (DCIR) [216],
and (d) the Fc receptor-like protein 5 (FCRL5) [217,218]. Neverthe-
less, the identity of the receptors involved is still a matter of some
controversy [219–226].
IVIg has been regarded as a pluripotent drug that canwork via many
different and complex pathways, depending on the types of autoim-
mune or inﬂammatory diseases being treated. Here, we would like to
focus on the role of sialic acid in the anti-inﬂammatory activity of IVIg
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and/or α2,6-sialylated IgG Fc (sFc) therapies.
5.3.1. Anti-inﬂammatory activity of sialylated IVIg (sIVIg)
The ﬁrst evidence that the glycan at the IgG Fc Asn297 residue is
indispensable for the anti-inﬂammatory activity of IVIg was provid-
ed by Kaneko et al. in 2006 [10]. In contrast to the fully glycosylated
IVIg preparation, both of the deglycosylated (PNGase F-treated) and
the desialylated (neuraminidase-treated) IVIg forms failed to sup-
press rheumatoid arthritis (RA) in mice [10]. It was later revealed
by Anthony et al. that only the addition of sialic acid residues with
α2,6-linkages, but not those with α2,3-linkages, on the IgG Fc N-
linked glycans could recapitulate the anti-inﬂammatory effects of
IVIg in vivo [9]. Such a crucial role of IVIg sialylation is also supported
by various studies in mice with different autoimmune conditions
[11,12,214,215,227].
Moreover, agalactosylated and asialylated IgG glycoforms have been
suggested to be pro-inﬂammatory due to their associationswith various
autoimmune and inﬂammatory diseases [106,228–231]. In contrast, a
recent study shows that, compared to CIDPpatientswith stable orwors-
ened conditions, those in remission have signiﬁcantly increased serum
IgG-Fc sialylation [232]. Besides acting as a negative regulator of B
cells proliferation independent of FcγRIIb expression [233,234], Fc-
sialylated glycovariants were shown to limit the pro-inﬂammatory IgG
effector functions through impairment of complement-mediated cyto-
toxicity [232]. Thus, sialylated IgG glycoforms have been hypothesized
to act as a switch to restore a balanced immune response. However,
which cellular receptor(s) can directly bind to sialylated IgG glycoforms
and how such interactions can trigger a downstream anti-inﬂammatory
effect remains an open question. Recent evidence from binding studies
suggests that classical FcγRs are unlikely candidates as the afﬁnity of IgG
for these receptors either remain unchanged [51] (Fig. 3B) or even de-
crease upon Fc-sialylation [10,235].
5.3.2. The receptor(s) for α2,6-sialylated Fc (α2,6-sFc)
One of the proposed candidate receptors for theα2,6-sFc is the C-
type lectin receptor DC-SIGN [214]. This notion was derived from the
observation that DC-SIGN-transfected CHO cells could deplete only
α2,6-sFc, but not α2,3-sFc, from cell culture supernatant [214]. Fur-
thermore, upon sIVIg treatment, DC-SIGN could replace its murine
ortholog SIGN-R1 to protect mice from serum-induced arthritis
[214,236]. In this scenario, sIVIg induced the production of IL-33,
which subsequently promoted the secretion of T-helper cell type 2
(TH2) cytokines, IL-4 and IL-13. Consequently, this led to an upregu-
lation of the inhibitory FcγRIIB expression and a downregulation of
the activating FcγRs on myeloid effector cells. In addition, a model
for the binding between DC-SIGN and sFc was proposed based on a
crystal structure of the CD23/IgE-Fc complex [54]. In this model,
non-sialylated IgG-Fc exists in an ‘open’ state with preferential bind-
ing to FcγRs, while sialylated IgG-Fc has a ‘closed’ conformation and
thus can interact with DC-SIGN.
Although the immunosuppression induced via direct interaction
with DC-SIGN has been demonstrated for a number of antigens [237,
238], whether this is true for α2,6-sFc remains debatable. As a type 2
C-type lectin receptor, DC-SIGN contains a carbohydrate recognition
domain (CRD) that selectively binds to high-mannose and fucosylated
glycans in a Ca2+-dependent manner [224,225,239,240]. Yet, none of
the current biophysical data indicates a direct interaction between DC-
SIGN and α2,6-sFc [223–225,239–242]. Recently, as discussed above, a
crystal structure of sialylated IgG Fc [46] has been solved and found to
be very similar to that of non-sialylated IgG Fc [243]. Furthermore, no
difference was observed for the binding afﬁnity of engineered IgG
glycoforms that were either hypersialylated, desialylated or deglycosyl-
ated to the extracellular region of the DC-SIGN tetramer [223].
Besides the biophysical data, other immunological studies using
human DC-SIGN expressing cells, such as human splenocytes andmonocyte-derived dendritic cells (moDCs), did not suggest a clear
indication for the involvement of DC-SIGN in the anti-inﬂammatory
activity of IVIg [244–247]. Although DC-SIGN was implicated in the
IVIg-mediated expansion of regulatory T (Treg) cells, this effect
was shown to be F(abʹ)2- but not Fc-dependent [248]. Also, human
DC-SIGN and murine SIGN-R1 differ considerably in terms of their
expression and anatomical distribution [249–252]. For instance,
whereas human DC-SIGN is present on subsets of monocytes [236],
myeloid dendritic cells (DCs) [253] and subcapsular sinus macro-
phages [254,255], murine SIGN-R1 is not expressed on such cell
types. Thus, whether DC-SIGN is the proper human homolog of
SIGN-R1 requires further investigation.
While a role for DC-SIGN is being re-evaluated, three alternative
sIVIg sensors have been proposed so far. They are the sialic acid-
binding immunoglobulin-type lectin (SIGLEC) CD22 [213], the C-
type lectin dendritic cell immunoreceptor (DCIR) [216], and the Fc
receptor-like protein 5 (FCRL5) [217,218]. Besides being able to
bind to N-glycans containing α2,6-linked sialic acid residues with
high speciﬁcity [256], CD22 was shown to mediate B-cell receptor
(BCR) signalling to promote apoptosis in mature human B lympho-
cytes upon treatment with sIVIg, but not with desialylated IVIg
[213]. Arguing against a role for B cells and CD22 is the observation
that mice deﬁcient in B cells or CD22 were still protected by IVIg
from ITP and serum-induced arthritis [220]. Although this study in-
dicates that IVIg can activate immunosuppressive pathways inde-
pendently of B cells and CD22, it should not be misinterpreted as
direct evidence against the ability of human CD22 to bind human
sFc. Instead, it should be understood that murine CD22 may not
strongly interact with human sFc.
The most common mammalian sialic acids are N-acetylneuraminic
acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), which are
structurally distinguished by only a single oxygen atom in the C-5
substituent [257]. While mice can synthesize both Neu5Ac and
Neu5Gc, humans can only synthesize Neu5Ac due to the non-
functional cytidine monophosphate-N-acetylneuraminic acid hy-
droxylase [258,259]. Yet, while murine CD22 shows a strong prefer-
ence for Neu5Gc, human CD22 can bind to both Neu5Ac and Neu5Gc
equally well [260]. As sIVIg is pooled from human donors and con-
tains Neu5Ac, sIVIg may not interact with murine CD22 sufﬁciently
enough to trigger, for instance, downstream BCR immunosuppres-
sive signalling.
With regards to the remaining two candidates, DCIR and FCRL5, cur-
rent evidence supporting their involvement in the anti-inﬂammatory
effects of IVIg is limited. DCIR has an extracellular CRD and an intracel-
lular immunoreceptor tyrosine-based inhibitory motif (ITIM) for trans-
duction of negative signals into cells [261]. Mice deﬁcient in DCIR were
susceptible to autoimmune diseases at later age due to excessive DC ex-
pansion [262]. Previously, it was shown that puriﬁed humanDCIR could
bind to fucose and mannose glycans like LewisB and Man3 with high
speciﬁcity [263], and that such DCIR-glycan interactions could result
in signalling via its ITIM motif [264]. Recently, Massoud et al. demon-
strated that murine DCIR could speciﬁcally bind to sialic-acid enriched
IgG (sIgG) in vitro [216]. Moreover, this interactionwas shown to be re-
sponsible for the expansion of Tregs, which alleviates allergic airways
disease in ovalbumin-sensitizedmice [216]. Although this is an interest-
ing ﬁnding, whether human DCIR can bind to sIgG in a similar manner
to murine DCIR requires further examination. Also, whether this DCIR-
sIgG interaction is responsible for the anti-inﬂammatory effects of IVIg
in other autoimmune conditions, especially where IgG autoantibodies
play a major role, have yet to be explored.
Human FCRL5, together with other Fc receptor-like (FCRL) mole-
cules (FCRL1–6), was discovered when searching for Fc receptor ho-
mologs [265,266]. While the intracellular domain of the classical
FcγRs has either an inhibitory ITIM or an activating ITAM motif,
FCRL5 has both ITIM and ITAM motifs in its cytoplasmic tail. FCRL5
is preferentially expressed on B cells [267] and is reported to be
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cently, it has been demonstarted that FCRL5 is a speciﬁc IgG receptor
[218,271]. While the classical FcγRs could interact solely with the Fc
region [20], high-afﬁnity binding to FCRL5 required intact full-length
IgG molecules [218]. Furthermore, whereas sialic acid enrichment of
IVIg using Sambucus nigra agglutinin (SNA) enhanced FCRL5-IgG in-
teractions, deglycosylation using PNGase F abrogated nearly all bind-
ing activity [218]. Although this study raises the possibility that
FCRL5may act as an sIVIg sensor, whether FCRL5 is indeed the recep-
tor for the α2,6-sFc has not been thoroughly evaluated. For instance,
direct comparisons of the binding afﬁnity to FCRL5 between Fc-
desialylated (neuraminidase-treated) and Fc-sialylated IVIg samples
are not yet available. At themoment, little is known about the immu-
noregulatory functions of FCRL5 in vivo.
Taken together, while a role for DC-SIGN is not clear, alternative sIVIg
sensors, namely CD22, DCIR and FCRL5, have been proposed. More evi-
dence is required to conﬁrm the identity of the receptor(s) for the
α2,6-sFc.
5.3.3. To sialylate or not to sialylate?
Despite supporting evidence for the therapeutic applications of
sialylated IVIg, there are arguments for sialic acid-independent anti-
inﬂammatory pathways. Indeed, sialylation has been reported to be dis-
pensable in three different in vitro systems [272–274], as well as in sev-
eral murine models of ITP [275,276], experimental autoimmune
encephalomyelitis (EAE) [277], arthritis [278] and herpes simplex
virus-induced encephalitis [279].
The debate on ‘to sialylate or not to sialylate’may be further compli-
cated by two main issues. The ﬁrst issue lies in the different protocols
that are used to generate sialylated IgG glycoforms. For instance, poly-
clonal IVIg puriﬁed by SNA lectin chromatography would be predomi-
nantly enriched for the F(abʹ)2-fragment instead of the Fc [36,276].
However, whether sialylation of F(abʹ)2 reduces the effectiveness of
IVIg, as observed by Guhr et al. [276], or whether this enhances the
anti-inﬂammatory activity, as described by Kasermann et al. [272], re-
quires further investigation. Meanwhile, a more effective method to
sialylate Fc fragment is the consecutive in vitro enzymatic treatment
with β1,4-galactosyltransferase and α2,6-sialyltransferases. Coupled
with rigorous industrial-scale protocols and stringent quality control
steps, Washburn et al. demonstrated that such enzymatic treatments
could successfully generate a tetra-sialylated Fc that was not only de-
void of undesirable glycan modiﬁcations but also capable of exerting a
more potent anti-inﬂammatory activity than the standard IVIg [11].
The second issue lies in the different dosing protocols for murine
models. For instance, in the prophylactic treatment ofmicewith passive
ITP, Schwab et al. administered IVIg 2 h before and counted platelets 4 h
after ITP induction [12]. In comparison, Guhr et al. employed a different
prophylactic scheme in which mice were given IVIg 24 h before and
their platelets were counted 16 h after ITP induction [276]. Variations
have also been observed in the murine therapeutic intervention:
while Schwab et al. used a constant daily dose of antiplatelet antibodies
to induce ITP [12], Leontyev et al. opted for dose-escalation [275]. Of
note, while patients receive IVIg upon a conﬁrmed diagnosis, mice in
many experiments are administered with IVIg prophylactically. Al-
though a recent study has demonstrated that there is a considerable
overlap between prophylactic and therapeutic IVIg treatments in mice
with ITP, arthritis and skin-blisteringdisease [12], it would bemore con-
sistent if future murine experiments can be shifted toward therapeutic
instead of prophylactic IVIg treatment.
To summarize, although IVIg may activate immunosuppressive
pathways independently of sialylation, certain autoimmune conditions
could be more effectively treated with sialic acid-enriched IgG
glycoforms. Given the extra cost associated with additional enrichment
steps for sialylated IgG, recombinant sialylated Fc fragments could be an
attractive therapeutic alternative to overcome the current shortage of
IVIg [280]. Care needs to be taken when translating the vast knowledgegained on the anti-inﬂammatory activity of IVIg frommurine models
to human subjects.
6. Concluding remarks
The presence of oligosaccharides attached at a single site on the IgG
Fc domain signiﬁcantly inﬂuences antibody effector functions. Recent
advances in the ﬁeld of antibody glycoengineering have provided suit-
able materials for both fundamental antibody structure–function rela-
tionship studies and for therapeutic applications. Manipulation of the
biosynthetic pathways of different hosts, including mammalian cells,
yeasts and plants, allows the production of selected antibody
glycoforms, especially the sialylated and non-fucosylated versions. Al-
ternatively, the preparation of homogeneous IgG glycoforms can be
achieved with the in vitro chemo-enzymatic glycosylation remodelling.
Thismethod has been successfully demonstrated on various therapeutic
monoclonal antibodies such as rituximab and trastuzumab
(Herceptin®).
In addition, emerging knowledge on how the Fc glycans contribute
to antibody effector functions has opened up new avenues for the ex-
ploitation of certain antibody glycoforms in the clinic. For example,
defucosylated antibodies have been reported not only to enhance
ADCC per se but also to be capable of evading the inhibitory effect of
serum IgG on ADCC.While defucosylated antibodies have been increas-
ingly utilized in cancer therapy, especially with the success of
obinutuzumab (Gazyva®) for the treatment of chronic lymphocytic leu-
kemia, sialylated versions have been discovered to be capable of sup-
pressing autoantibody-driven inﬂammation. However, which
receptor(s) can interact with the sialylated IgG glycoforms and how
such interactions induce the anti-inﬂammatory activity has been an ac-
tive ﬁeld of research.
In conclusion, a better understanding of the structure and function of
different antibody glycoforms can provide uswith new opportunities to
engineer antibody therapeutics with optimal efﬁcacy. Speciﬁcally, de-
ﬁning the regulation of IgG glycosylation may represent a promising
strategy for ﬁne-tuning IgG-based recombinants for cancer and autoim-
mune diseases.
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